Service Quote Request
Please fill out the form below with your detailed inquiry.
Selecting the right AAV serotype is critical for achieving efficient gene transfer to adipose tissue. While AAV8 has been widely used for metabolic research, AAV(Rec2) has emerged as an engineered capsid with significantly improved adipose tropism.
Key Comparison
🧬 AAV8
🧬 AAV(Rec2)
✅ Local adipose depot injection (WAT or BAT): AAV(Rec2) is generally the preferred choice because it consistently provides higher transduction efficiency and stronger transgene expression than AAV8.
✅ Intraperitoneal (i.p.) administration: AAV(Rec2) has demonstrated efficient targeting of visceral adipose tissue while reducing off-target expression compared with conventional serotypes.
✅ Systemic intravenous (IV) administration: Both AAV8 and AAV(Rec2) can transduce adipose tissue, but significant liver transduction may still occur. Tissue-specific promoters or liver de-targeting strategies (e.g., miR-122 target sequences) are recommended when adipose-specific expression is desired.
For noninvasive monitoring of adipose transduction, luciferase reporters provide a convenient solution.
At SignaGen Laboratories, we offer both pre-made AAV8 luciferase vectors and custom-packaged AAV(Rec2) vectors to support adipose tissue research.